A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma

Lung Cancer

Volumn 50, Issue 1, 2005, Pages 75-82

  Berghmans, T ^a   Lafitte, J J ^b   Paesmans, M ^a   Stach, B ^c   Berchier, M C ^d   Wackenier, P ^e   Lecomte, J ^f   Collon, T ^g   Mommen, P ^h   Sculier, J P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Cabinet Médical Dampierre   (France)

^d Hôpital d'Hayange   (France)

^e Centre Hospitalier Universitaire Ambroise Pare   (Belgium)

^f Centre Hospitalier Universitaire de Charleroi   (Belgium)

^g Centre Hospitalier Intercommunal Le Raincy Montfermeil   (France)

^h ELCWP   (Belgium)

Author keywords

Chemotherapy; Cisplatin; Epirubicin; Malignant mesothelioma; Prognostic factors

Indexed keywords

CISPLATIN; EPIRUBICIN;

ADULT; AGED; ALOPECIA; ARTICLE; BLEEDING; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CARDIOTOXICITY; CELL COUNT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; EPITHELIUM; FEMALE; HEARING LOSS; HISTOPATHOLOGY; HUMAN; INFECTION; LEUKOPENIA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTIVARIATE ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE; SKIN METASTASIS; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; URINARY DYSFUNCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; EPIRUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 24744463569     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.05.007     Document Type: Article

References (21)

1. N.J. Vogelzang, L.B. Weissman, J.E. Herndon, K.H. Antman, M.R. Cooper, and J.M. Corson Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B Phase II study J Clin Oncol 12 7 1994 1436 1442
2. H.I. Pass, K. Kranda, B.K. Temeck, I. Feuerstein, and S.M. Steinberg Surgically debulked malignant pleural mesothelioma: results and prognostic factors Ann Surg Oncol 4 3 1997 215 222
3. S. van Ruth, P. Baas, and F.A. Zoetmulder Surgical treatment of malignant pleural mesothelioma: a review Chest 123 2003 551 561
4. D.E. Maziak, A. Gagliardi, A.E. Haynes, J.A. Mackay, and W.K. Evans Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary Lung Cancer 48 2 2005 157 169
5. Chahinian AP. Treatment of malignant mesothelioma: radiotherapy and chemotherapy. In: Robinson BW, Chahinian AP, editors. Mesothelioma. London: Martin Dunitz; 2002. p. 209-22.
6. S.T. Ong, and N.J. Vogelzang Chemotherapy in malignant pleural mesothelioma: a review J Clin Oncol 14 3 1996 1007 1017
7. C.W. Ryan, J. Herndon, and N.J. Vogelzang A review of chemotherapy trials for malignant mesothelioma Chest 113 Suppl. 1 1998 66S 73S
8. T. Berghmans, M. Paesmans, Y. Lalami, I. Louviaux, S. Luce, and C. Mascaux Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis Lung Cancer 38 2002 111 121
9. T. Berghmans, J.J. Lafitte, C. Mascaux, A.P. Meert, M. Paesmans, and J.P. Sculier Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis Cancer Ther 1 2003 245 256
10. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, and P. Ruffie Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
11. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 1989 1 10
12. J.E. Herndon, M.R. Green, A.P. Chahinian, J.M. Corson, Y. Suzuki, and N.J. Vogelzang Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B Chest 113 3 1998 723 731
13. D.A. Fennell, A. Parmar, J. Shamash, M.T. Evans, M.T. Sheaff, and R. Sylvester Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials J Clin Oncol 23 1 2005 184 189
14. M.F. Muers, R.M. Rudd, M.E. O'Brien, W. Qian, A. Hodson, and M.K. Parmar BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112 Thorax 59 2 2004 144 148
15. A. Ardizzoni, R. Rosso, F. Salvati, V. Fusco, A. Cinquegrana, and M. De Palma Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma: an Italian Lung Cancer Task Force (FONICAP) Phase II study Cancer 67 12 1991 2984 2987
16. J.L. Breau, C. Boaziz, J.F. Morère, D. Sadoun, and L. Israël Chemotherapy with cisplatin, adriamycin, bleomycin and mitomycin C, combined with systemic and intrapleural hyaluronidase in stage II and III pleural mesothelioma Eur Respir Rev 3 1993 223 225
17. A.P. Chahinian, K. Antman, M. Goutsou, J.M. Corson, Y. Suzuki, and C. Modeas Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B J Clin Oncol 11 8 1993 1559 1565
18. H. Henss, H.H. Fiebig, J. Schildge, H. Arnold, and J. Hasse Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura Onkologie 11 3 1988 118 120
19. H.S. Parra, L. Tixi, F. Latteri, S. Bretti, M. Alloisio, and A. Gravina Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP) Cancer 92 3 2001 650 656
20. M.C. Pennucci, A. Ardizzoni, P. Pronzato, M. Fioretti, C. Lanfranco, and A. Verna Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force Cancer 79 10 1997 1897 1902
21. D.M. Shin, F.V. Fossella, T. Umsawasdi, W.K. Murphy, M.H. Chasen, and G. Walsh Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma Cancer 76 11 1995 2230 2236